Celsion (CLSN) Receives a Buy from Brookline Capital Markets

In a report issued on November 15, Kumaraguru Raja from Brookline Capital Markets reiterated a Buy rating on Celsion (CLSNResearch Report), with a price target of $9.00. The company’s shares closed last Monday at $1.23, close to its 52-week low of $1.05.

According to TipRanks.com, Raja has currently no stars on a ranking scale of 0-5 stars, with an average return of -21.6% and a 35.5% success rate. Raja covers the Healthcare sector, focusing on stocks such as Progenics, SCYNEXIS, and Chiasma.

Currently, the analyst consensus on Celsion is a Moderate Buy with an average price target of $8.50, a 486.2% upside from current levels. In a report issued on November 4, JonesTrading also maintained a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.63 and a one-year low of $1.05. Currently, Celsion has an average volume of 140.8K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLSN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.